1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Ardelyx Trying To Rewrite Tenapanor’s Narrative: Less Side Effects, New Biomarker

Having regained full rights to the first-in-class NHE3 inhibitor from AstraZeneca, Ardelyx plans a Phase III study in IBS-C and a Phase IIb study in hyperphosphatasia related to kidney dialysis before year’s end.

Roughly six weeks after regaining rights to first-in-class NHE3 inhibitor tenapanor from AstraZeneca PLC, Ardelyx Inc. is planning a Phase IIb study in hyperphosphatasia where it hopes to show lower doses can sufficiently reduce serum phosphate levels while minimizing adverse events that led to treatment discontinuations in a prior Phase IIb trial.

During its investor day presentation July 14, the Fremont, Calif.-based company outlined plans for that program as well for Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By Tim Casey

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

Drug Sponsors Can Help Shape Agenda For FDA/EMA Pediatric ‘Cluster’ Calls

 
• By Sue Sutter

Companies can propose specific issues for discussion during the regulators’ monthly teleconferences, which focus on finding areas of agreement and reasons for nonalignment on specific pediatric development plans or general issues.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.